Key Highlights

  • Inaxaplin reduced UACR 42.7% at week 13 in AMKD patients with modest proteinuria, but only 17.3% in patients with type 2 diabetes.
  • The Phase 2/3 AMPLITUDE trial is fully enrolled, with an interim eGFR analysis planned for early 2027.
  • Q2 2026 Revenue rose 12% to $3.33 billion; Vertex raised 2026 revenue guidance to $13.1-$13.2 billion.
  • Vertex agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, an Equity value of about $10.0 billion, adding a fifth therapeutic area in rare endocrine disease.

New data from Vertex Pharmaceuticals (NASDAQ:VRTX) strengthen the case that inaxaplin, its experimental pill for APOL1-mediated kidney disease, can reduce a key marker of kidney damage in a broader group of patients than first studied. For investors, the Sept. 22 results matter less as a near-term revenue event and more as a signal that Vertex's effort to build a kidney Franchise beyond cystic fibrosis is on track ahead of a pivotal interim readout in early 2027.

In the Phase 2b AMPLIFIED study, patients with modest levels of protein in their urine saw urine albumin-to-creatinine ratio, or UACR, fall 42.7% after 13 weeks of treatment. A second cohort of patients who also had type 2 diabetes showed a smaller 17.3% reduction. Vertex also said its Phase 2/3 AMPLITUDE trial, which could support an Accelerated Approval filing, has completed enrollment.

APOL1-mediated kidney disease, or AMKD, affects about 150,000 people in the United States and Europe, according to Vertex, and there are currently no approved therapies that target its underlying cause. That combination of a genetically defined population and no direct competition is what makes the program strategically important.

AMKD is driven by inherited variants in the APOL1 gene, which are found predominantly in people of recent African ancestry, and it tends to cause faster progression toward kidney failure than many other forms of chronic kidney disease. Inaxaplin is an oral small molecule designed to inhibit APOL1 function directly, targeting the root cause of the disease rather than managing symptoms. That approach mirrors the strategy Vertex used in cystic fibrosis, where medicines aimed at the underlying genetic defect built its dominant franchise.

Breaking Down the AMPLIFIED Results

AMPLIFIED was a single-arm, open-label study in which patients took 45 milligrams of inaxaplin once daily on top of standard care. Cohort 1, made up of patients with modest proteinuria, enrolled 23 people, of whom 22 were analyzed. Their 42.7% UACR reduction at week 13 had a 95% confidence interval of minus 58.3% to minus 21.1%. A secondary measure, urine protein-to-creatinine ratio, fell 44.7%.

Cohort 2, which enrolled 18 patients with type 2 diabetes and analyzed 17, posted a 17.3% UACR reduction, with a confidence interval of minus 36.3% to plus 7.2%. Because that interval crosses zero, the result in diabetic patients is less conclusive, although the protein-to-creatinine ratio fell 25.4%.

Inaxaplin was generally well tolerated, Vertex said. There were no serious adverse events, and the most common side effect was headache, reported in 7.3% of participants. Five subjects had transient elevations in liver enzymes known as transaminases. Chief Medical Officer Carmen Bozic and Stanford University's Glenn Chertow, who chairs the study's steering committee, were quoted in the release.

Why AMPLITUDE Is the Bigger Catalyst

The single-arm, open-label design and small cohort sizes mean AMPLIFIED is supportive rather than definitive. The pivotal test is AMPLITUDE, a global placebo-controlled trial whose primary endpoint is the rate of decline in estimated glomerular filtration rate, or eGFR, over two years. Vertex plans an interim analysis in early 2027, and if positive, the company said it could support a filing for accelerated approval.

Proteinuria is a recognized marker of kidney damage, but regulators ultimately want evidence that a drug slows loss of kidney function. That is why the eGFR readout will carry far more weight for inaxaplin's commercial prospects than the latest data.

Financial Footing and the Crinetics Deal

Vertex's core cystic fibrosis Business continues to fund its expansion. In its second-quarter 2026 results released Aug. 3, the company reported revenue of $3.33 billion, up 12% from $2.96 billion a year earlier. Trikafta/Kaftrio contributed about $2.50 billion and the newer once-daily Alyftrek $573.6 million. Newer products are growing from a small base: Casgevy, the gene-editing therapy for sickle cell disease and Beta thalassemia, generated $76.4 million, while non-opioid pain drug Journavx added $49.6 million. Vertex said Casgevy revenue grew 78% from the prior quarter and that Journavx topped 900,000 prescriptions in the first half of 2026.

GAAP Net Income was $1.10 billion, or $4.31 per diluted share, and non-GAAP Earnings were $4.73 per share. Vertex raised its 2026 revenue guidance to $13.1 billion to $13.2 billion, from $12.95 billion to $13.1 billion, and ended June with $13.6 billion in cash, cash equivalents and marketable securities.

Vertex has also added a fifth therapeutic area. It agreed to acquire Crinetics Pharmaceuticals (NASDAQ:CRNX) for $85 per share in cash, an equity value of about $10.0 billion, or about $8.8 billion net of estimated cash, bringing in rare endocrine disease medicines. Vertex has since announced that the Acquisition is complete.

Kidney Disease in the Broader Pipeline

Inaxaplin is one of several kidney programs. Povetacicept, for IgA nephropathy, has a Food and Drug Administration decision date of Nov. 30, 2026, according to Vertex's second-quarter release. Together, these programs position Vertex against larger players in nephrology such as Novartis (NYSE:NVS), which is also targeting IgA nephropathy, while AMKD remains an area without an approved disease-targeting therapy.

Balancing the Risks

  • Clinical risk: The AMPLITUDE interim analysis could Fail to show a sufficient effect on eGFR, which would weaken the accelerated approval path.
  • Mixed subgroup data: The weaker, statistically inconclusive result in diabetic patients may limit the drug's reach within AMKD.
  • Safety monitoring: Liver enzyme elevations, though transient, will be watched closely in larger trials.
  • Concentration: Cystic fibrosis drugs still generate the vast majority of revenue, so Diversification efforts must deliver over time.
  • Integration: Absorbing Crinetics adds execution and cost demands.

The FDA Decision and Data Readouts Ahead

The most immediate catalyst is the Nov. 30 FDA decision on povetacicept in IgA nephropathy. Vertex's third-quarter results, expected in early November based on its usual schedule, should provide the first look at Crinetics' contribution and an update on 2026 guidance. Investors are also awaiting data from the VX-828 cystic fibrosis program and the VX-670 myotonic dystrophy study, both guided for the second half of 2026, as well as updated timelines for zimislecel in type 1 diabetes. The AMPLITUDE interim analysis in early 2027 remains the defining event for inaxaplin.